Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 7/20 | 0.90 |
| ▸ | DRD2 | P14416 | 6/20 | 0.90 |
| ▸ | DRD3 | P35462 | 3/20 | 0.90 |
| ▸ | HTR1A | P08908 | 3/20 | 0.73 |
| ▸ | TH | P07101 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | HTR2B | P41595 | 2/20 | 0.63 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1204548 | 1.00 | DRD1 (0.90) | DRD1DRD2DRD3HTR1ATH | |
| SCHEMBL1204062 | 0.95 | DRD1 (1.00) | DRD1DRD2DRD3HTR1ATH | |
| SCHEMBL1203363 | 0.95 | DRD1 (1.00) | DRD1DRD2DRD3HTR1ATH | |
| SCHEMBL1204538 | 0.90 | DRD1 (0.86) | DRD1DRD2DRD3HTR1ATH | |
| SCHEMBL1204536 | 0.90 | DRD1 (0.86) | DRD1DRD2DRD3HTR1ATH | |
| SCHEMBL12877939 | 0.87 | DRD1 (0.71) | DRD1DRD2DRD3HTR1ATH | |
| SCHEMBL15180898 | 0.85 | DRD2 (0.87) | DRD1DRD2DRD3HTR1ATH | |
| SCHEMBL15170348 | 0.85 | DRD1 (0.86) | DRD1DRD2DRD3HTR1ATH | |
| SCHEMBL1204057 | 0.85 | DRD1 (0.78) | DRD1DRD2DRD3HTR1ATH | |
| SCHEMBL1204059 | 0.85 | DRD1 (0.78) | DRD1DRD2DRD3HTR1ATH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431591-B2 | R(−)-2-methoxy-11-hydroxyaporphine and derivatives thereof | THE MCLEAN HOSPITAL CORPORATION (US) | 2013-04-30 | — | — | US | claimed |
| US-20110034446-A1 | R(-)-2-METHOXY-11-HYDROXYAPORPHINE AND DERIVATIVES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2011-02-10 | — | — | US | claimed |
| WO-2009009083-A1 | R(-)-2-METHOXY-11-HYDROXYAPORPHINE AND DERIVATIVES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2009-01-15 | — | — | WO | claimed |
| US-8431591-B2 | R(−)-2-methoxy-11-hydroxyaporphine and derivatives thereof | THE MCLEAN HOSPITAL CORPORATION (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110034446-A1 | R(-)-2-METHOXY-11-HYDROXYAPORPHINE AND DERIVATIVES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034446-A1 | R(-)-2-METHOXY-11-HYDROXYAPORPHINE AND DERIVATIVES THEREOF | SNCA, HTR3A, PARK7 | DRD1 30/4885DRD2 18/4885DRD3 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.